CASI PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
CASI PHARMACEUTICALS, INC. (CASIF) had Accumulated Other Comprehensive Income of -$1.78 million as of 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-05-15
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.78M.
- 2024-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.77M.
- 2023-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.20M.
- 2022-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$703.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2025-12-31 | -$1.78M 20-F · filed 2026-05-15 |
| 2024-12-31 | -$1.77M 20-F · filed 2026-05-15 |
| 2023-12-31 | -$1.20M 20-F · filed 2025-03-31 |
| 2022-12-31 | -$703.00K 20-F · filed 2024-03-28 |
| 2021-12-31 | $1.95M 20-F · filed 2023-04-26 |